Oncotarget

Research Papers:

p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy

Brigitte Bisaro, Marianna Sciortino, Shana Colombo, Maria Pilar Camacho Leal, Andrea Costamagna, Isabella Castellano, Filippo Montemurro, Valentina Rossi, Giorgio Valabrega, Emilia Turco, Paola Defilippi and Sara Cabodi _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:4442-4453. https://doi.org/10.18632/oncotarget.6710

Metrics: PDF 1357 views  |   HTML 1572 views  |   ?  


Abstract

Brigitte Bisaro1, Marianna Sciortino1, Shana Colombo1, Maria Pilar Camacho Leal1, Andrea Costamagna1, Isabella Castellano2, Filippo Montemurro3, Valentina Rossi3, Giorgio Valabrega4,2, Emilia Turco1, Paola Defilippi1, Sara Cabodi1

1Department of Biotechnology and Health Sciences, University of Torino, Torino, Italy

2Department of Medical Sciences, University of Torino, Torino, Italy

3Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Torino, Italy

4Department of Oncology, University of Torino, Torino, Italy

Correspondence to:

Sara Cabodi, e-mail: sara.cabodi@unito.it

Keywords: p130Cas, ErbB2, autophagy, breast cancer resistance

Received: June 16, 2015     Accepted: November 25, 2015     Published: December 21, 2015

ABSTRACT

Overexpression of the ErbB2/HER2 receptor tyrosine kinase occurs in up to 20% of human breast cancers and correlates with aggressive disease. Several efficacious targeted therapies, including antibodies and kinase inhibitors, have been developed but the occurring of resistance to these agents is often observed. New therapeutic agents targeting the endocytic recycling and intracellular trafficking of membrane in tumor cells overexpressing ErbB2 are actually in clinical development. Nevertheless the mechanisms underlying ErbB2 downregulation are still obscure. We have previously demonstrated that the overexpression of the p130Cas adaptor protein in ErbB2 positive breast cancer, promotes tumor aggressiveness and progression. Here we demonstrate that lowering p130Cas expression in breast cancer cells is sufficient to induce ErbB2 degradation by autophagy. Conversely, p130Cas overexpression protects ErbB2 from degradation by autophagy. Furthermore, this autophagy-dependent preferential degradation of ErbB2 in absence of p130Cas is due to an increased ErbB2 ubiquitination. Indeed, the overexpression of p130Cas impairs ErbB2 ubiquitination by inhibiting the binding of Cbl and CHIP E3 ligases to ErbB2. Finally, our results indicate that p130Cas-dependent ErbB2 protection from degradation by autophagy may alter the sensitivity to the humanized monoclonal antibody trastuzumab. Consistently, in human ErbB2 positive breast cancers that develop resistance to trastuzumab, p130Cas expression is significantly increased suggesting that elevated levels of p130Cas can be involved in trastuzumab resistance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6710